PhD candidate Emily Sholi has received an NIH fellowship to further her ribosome research, investigating how pathogens inhibit host ribosomes.

Research by Andrei Korostelev, PhD, and Anna Loveland, PhD, shows that the ribosome plays an unexpected role in the activation of angiogenin, allowing it to cleave transfer RNA, thereby halting protein production. These findings shed new light on angiogenin functioning and may have important implications for the design of cancer therapeutics and neurodegenerative disease treatments.  

The BRIDGE Fund supports critical research milestones for inventions and discoveries that have high potential to change the course of disease and continues to grow, increasing from approximately $1 million per year in 2019 to $3 million in 2024.

A recent survey of health care professionals showed nearly 60 percent of participants encountered patients whose infections didn’t respond to any antibiotic. Andrei Korostelev, PhD, says by studying the biology of bacterial cells, effective new antibiotics can be developed.